A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer

Everett E. Vokes, Robert Figlin, Howard Hochster, Michael Lotze, Mary Ellen Rybak

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

PURPOSE: Recombinant human interleukin-4 is a pleiotropic cytokine that has shown antitumor activity in preclinical models and activity in phase I clinical trials. PATIENTS AND METHODS: This was a randomized phase II study testing two doses of recombinant human interleukin-4 (0.25 μg/kg and 1.0 μg/kg) administered subcutaneously three times per week in advanced non- small cell lung cancer. RESULTS: Sixty-three patients were enrolled (22 receiving 0.25 μg/kg and 41 taking 1.0 μg/kg); the median age was 61 years. Tumor histology included adenocarcinoma (41 patients), squamous cell carcinoma (12 patients), and other types (10 patients). The initial stage of disease was IIIb in 11 patients and IV in 52. Forty-four patients had received prior combination chemotherapy, predominantly cisplatin based. Recombinant human interleukin-4 was well tolerated, with no myelosuppression or deviations of liver enzymes, bilirubin, or blood glucose. The most frequent symptoms (any grade) in the 0.25-μg dose group were fatigue (13/22) and fever (8/22). Severe vomiting and dyspnea were observed in one patient each. In the 1.0-μg dose group, a similar toxicity pattern (any grade) was seen, with fatigue (18/41), fever (14/41), and anorexia (12/41). One patient each had severe hypotension and chest pain. One patient was withdrawn from the study because of a perforated duodenal ulcer. Fifty-five patients were evaluable for response. In the 1.0-μg group, there was one partial response of > 5.5 years' duration, and eight patents had stable disease of 106 to 350 days' duration. All patents had stage IV disease, and 24 patients had progressed during previous chemotherapy. In the 0.25-μg group, one patient had stable disease. DISCUSSION: Recombinant human interleukin-4 can be administered salty and may have antitumor activity in non-small cell lung cancer. The higher dose (1.0 μg/kg) may be associated with a higher incidence of stable disease. In view of the low toxicity seen at both dose levels, a phase II study investigating higher recombinant human interleukin- 4 doses is ongoing. Recombinant human interleukin-4 should be explored further, alone or in combination with other cytokines, chemotherapy, or radiotherapy.

Original languageEnglish (US)
Pages (from-to)46-51
Number of pages6
JournalCancer Journal from Scientific American
Volume4
Issue number1
StatePublished - 1998
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this